Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety profile of a new prolonged release
formulation of octreotide acetate, C2L-OCT-01 PR, administered intra muscularly every 4, 5 or
6 weeks in acromegalic patients.